Psycho-Babble Medication Thread 846164

Shown: posts 1 to 10 of 10. This is the beginning of the thread.

 

Social phobia was diagnosed in 50% of PD patients.

Posted by Marty on August 14, 2008, at 11:55:53

http://www.ncbi.nlm.nih.gov/pubmed/18661550?ordinalpos=14&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Dopamine is implicated in Social Phobia and this has been consistenly shown (linked). A social phobic has 6 more chances of developping Parkinson (or was it 1 in 6 ? major difference but I doesn't have time to research it right now). Now they found out that 1/2 the Parkinson sufferers develop social phobia...

My grand-father died of Parkinson a couple years ago. I'm not aware that he was social phobic in his life or while being sick. For my part, I'm social phobic and have alot of atypical or strong reaction to (anti)dopaminergic drugs... all kind of bad somehow.

Any social phobic here with good experience with (anti)dopaminergic drugs / specific Parkinson drugs ?

Anyone knows of to check for common implicated/suspected gene variation and such BETWEEN Social Phobia and Parkinson ? I know there are good database on the net but I never checked them out..

/\/\arty

 

Re: Social phobia was diagnosed in 50% of PD patients. » Marty

Posted by Phillipa on August 14, 2008, at 12:38:42

In reply to Social phobia was diagnosed in 50% of PD patients., posted by Marty on August 14, 2008, at 11:55:53

Marty first up on google looks like a good view of all that is good for social phobia. Will try and find more with parkinsons. Love Phillipa


Symptoms of Social Anxiety Disorder:
Social Anxiety Disorder is a persistent fear of one or more situations in which the person is exposed to possible scrutiny by others and fears that he or she may do something or act in a way that will be humiliating or embarrassing. It exceeds normal "shyness" when it leads to excessive social avoidance and substantial social or occupational impairment. Feared activities may include most any type of social interaction, especially small groups, dating, parties, talking to strangers, restaurants, etc. Physical symptoms include "mind going blank", fast heartbeat, blushing, stomach ache. Cognitive distortions are a hallmark, and learned about in CBT. Thoughts are often self-defeating and inaccurate.


Neurobiology of Social Anxiety Disorder:
Dysregulation of neurotransmitter function in the brain is thought to play a key role in Social Phobia (SP). Specifically, dopamine (DA), serotonin (SE), and / or GABA dysfunction are hypothosized in most cases of SP. in varying degrees depending on the individual. The MAOI antidepressant "phenelzine" (Nardil) uniquely boosts levels of all three - and is probably the single most effective (single drug) treatment for Social Phobia.

There is strong evidence for dopamine dysfunction in SP. Comorbidies with other DA hypofunction disorders such as atypical depression, dysthymia, attention deficit disorder (ADD), and alcoholism are common. It has been noted that those with generalized Liebowitz observed in comparison studies between the TCA "imipramine" (Tofranil) and the MAOI "phenelzine" (Nardil) that while phenelzine was extremely effective in treating Social Anxiety, imipramine showed no efficacy - with the primary difference in the two drugs being the marked pro-DA effect of Nardil.

Since the 1990's, evidence has emerged that an area of the brain called the striatum is different in patients with generalized Social Anxiety Disorder. More recent studies have switched focus to the amygdala, where evidence of abnormality accumulates. The amygdala is a core "primitive" part of the brain where many "automatic" animal type functions are regulated or controlled, such as fear and startle response, anxiety, sex, and aggression.


Research Past and Present:
Current research trends lean towards earlier recognition and treatment of SP. As the "world's most neglected anxiety disorder" becomes more understood by the public, Social Anxiety Disorder will begin to be diagnosed far more frequently in the pre-teen or teen years, resulting in earlier treatment, more "normal" social development, and less later life complications. In my case, during my 3rd grade year I had a 2 months bout of "school phobia", which commonly predicts SP in adulthood. Although Nardil and Klonopin existed at that time, the psychiatric diagnosis of Social Phobia did not. It was not until the early 1990's that key studies began for the medication treatment of SP. Liebowitz (Nardil), and Davidson (Klonopin) were the early pioneers towards highly effective SP medication treatment. Nardil and Klonopin remain the most reliably effective medications to treat Social Anxiety Disorder.


--------------------------------------------------------------------------------
Treatments for Social Anxiety Disorder:

Psychological Treatment:
Among possible psychological treatments for Social Anxiety Disorder, the best studied are CBT (Cognitive Behavioral Therapy) and CGBT (Cognitive Group Behavioral Therapy). While CBT and CGBT can often be helpful, medication treatments have been shown to produce more robust and dramatic improvement of symptoms. Patients with mild symptoms (as well as children or adolescents with Social Anxiety), may wish to pursue CBT or CGBT treatment methods as their first approach, while those with more significant or stubborn symptoms may prefer to use CBT as an adjunct to medication treatment. Good CBT therapists for SP are located primarily in larger cities. The best places to look are probably at large University Clinics or Health Centers.

Research suggests that "general" or "supportive" psychotherapy is also helpful for many patients with Social Anxiety Disorder. This is probably especially true in more moderate and severe cases where issues such as low self esteem and other psychological and/or adjustment difficulties may be more pervasive. Currently there is no evidence that CBT is more, or less, effective than other psychotherapy techniques in the treatment of Social Anxiety. There are no clear guidelines, and one is probably best off trusting their own instincts of what is best for them.

Medication Treatment:
Medication treatment is the "tried and true" method to effectively treat Social Anxiety Disorder. Research trials for the treatment of Social Anxiety are still limited primarily to "monotherapy" treatment (one drug by itself). In actual practice, it is often the case that 2 or more medications are used in combination (polypharmacy). There are likely to be many different treatments (single drug or combinations) which are helpful for a given individual. Experimentation affords one an opportunity to find out which treatments are most satisfactory for them. Despite increasing recognition of "the world's most neglected anxiety disorder" - most Dr's even now in *2007* continue to have relatively little experience (and even less skill) in treating patients with Social Anxiety. Patient self-education continues to play a key role for those wishing to ensure that they receive the appropriate medical intervention they deserve.

A Medication Treatment Algorithm for Social Anxiety:
One reasonable algorithm of trial is as follows:
(Goal is typically effectiveness and tolerability over the long term):

1) Antidepressant
a) SSRI, Effexor, moclobomide ... else try ...
b) MAOI (Nardil)

2) Benzodiazepine
a) Klonopin (alone)
b) Klonopin + Antidepressant (any above)
c) Xanax

3) May wish to augment (add) any of following: (Note: Most of these unstudied for SP)
a) Provigil (modafinil): Mild stimulant. Very low doses 20-100mg/day, divided
b) caffeine: Mild stimulant.
c) Neurontin (gabapentin): Anticonvulsant, may be sedating
d) Keppra (levetiracetam): Anticonvulsant, may be sedating

CERTAIN COMBINATIONS OR SINGLE DRUGS DANGEROUS: CHECK WITH DOCTOR FOR ALL TREATMENT RECOMMENDATION

--------------------------------------------------------------------------------
SSRI's

Several SSRI's have in recent years gained FDA approval in the treatment of Social Anxiety Disorder. During this time the SRI's have also come to be labeled the first line treatment for Social Anxiety Disorder in the general medical community.

Two SSRI's (Paxil and Zoloft) and one SNRI (Effexor XR) - are the only FDA approved drugs for SP at this time. Because of these recent FDA approvals and a relatively low risk of serious adverse events related to overdose and drug interactions, the SRI's are quite easy and legally safe for general physicians and psychiatrists to prescribe. Most Dr's will now initially prescribe an SRI when a previously untreated patient presents with symptoms of Social Anxiety Disorder.

SRI's are quite helpful in the treatment of SP symptoms. Their usefulness in SP is increased by the fact that they are effective not only in some of the direct symptoms of SP itself, but are also very helpful for a number of other common co-occurring disorders which may be present. These include dysthymia, depression, panic, general anxiety, and obsessive compulsive disorder (OCD).

With the exception of Prozac, SSRI's are used predominantly by women in long term treatment, who tolerate and respond to them better than males.

------------------

Prozac (fluoxetine): The "activating" SSRI with the least side effects - particularly for males. Considered an "atypical SSRI", with effects somewhere in between the SNRI "Effexor" and the other SSRI's.

Zoloft (sertraline): May be activating or sedating. Common side effects: sexual dysfunction, apathy.

Paxil CR (paroxetine): May be sedating. Common side effects: sexual dysfunction , apathy, weight gain.

"Paxil CR" was released in early 2004 when the patent on "Paxil" expired, to acquire a new patent and retain inflated prices on the newer CR version. There is no known difference in efficacy between generic and "CR". There is limited need for a "CR" version since the half life of generic Paxil is near ideal; with an FDA recommended once daily dosing.

Celexa (citalopram): May be activating or sedating. Common side effects: sexual dysfunction, apathy.

Lexapro (escitalopram): May be activating or sedating. Common side effects: sexual dysfunction, apathy.

Lexapro was released in 2002 when the patent expired on Celexa (same manufacturer) to acquire a new patent and retain inflated prices on the newer version. Lexapro contains the same active ingredient as Celexa (escitalopram) with no known clinical differences between the two medications.


--------------------------------------------------------------------------------
"New generation" Antidepressants

These include Effexor XR, Cymbalta, Wellbutrin SR, Remeron and Serzone. They each have fairly different characteristics from each other and from the SSRI's. Used alone, any of them may be mildly helpful for primary SP. Augmentation may modify the effects of any of these to create a more effective SP treatment.

Effexor XR (venlafaxine): Effexor is an "SNRI" (serotonin and norepinephrine reuptake inhibitor). The NE reuptake results in a more activating and energizing profile than that of the SSRI's. Effexor is usually only mildly helpful for primary SP when taken alone. It is a powerful antidepressant which is ironically also effective for GAD (Effexor often increases anxiety in patients with primary Social Anxiety Disorder).

Cymbalta (duloxetine): Cybalta, like Effexor, is an "SNRI" (serotonin and norepinephrine reuptake inhibitor). Cymbalta, released in 2005, differs from Effexor mainly in that it is comparatively more noradrenergic. Cymbalta is not likely to be any more useful for primary Social Anxiety Disorder than Effexor XR ... if anything less so.

Wellbutrin XR (bupropion): Wellbutrin boosts DA and NE, with little effect on SE. It is activating and does not cause weight gain or sexual side effects. It is more similar to stimulants (especially Ritalin) - then to SRI's. It is effective in depression and dysthymia, and one study shows possible efficacy in SP. In practice it tends to leave most with SP still feeling quite anxious. The addition of a serotonergic axiolytic (especially Xanax) can be effective.

Remeron (mirtazapine): Remeron enhances NE activity and has mixed SE effects (enhances 5ht(1) transmission but antagonizes 5ht(2) and 5ht(3) receptors). Remeron also has strong antihistamine effects, which may explain it's prominent sedative effects. Overall, Remeron usually causes significant sedation and/or irritability, and is infrequently used.


--------------------------------------------------------------------------------
TCA's

The TCA's (tricyclic) antidepressants are ineffective in the treatment of primary SP. TCA's emerged in the 1950's along with the MAOI's, and while there are still about 10 of them marketed in the USA, their use has been substantially replaced by the newer antidepressants.

Tofranil (imipramine): This once popular TCA was often used for depression, panic, and GAD.


--------------------------------------------------------------------------------
MAOI's

The MAOI "Nardil" is definitely the MOST powerful and effective antidepressant for Social Phobia.

Nardil (phenelzine): Nardil usually works great for SP! It the "Gold Standard" antidepressant for SP. Nardil is excellent for many other anxiety and depressive disorders also. Reports of Nardil side effects are frequently exaggerated, particularly since Nardil's side effects typically take 2-4 months to diminish or disappear. After several months Nardil tends to cause less side effects than SRI's across comparable dose ranges, with the exception of Prozac. Dietary retrictions are quite minimal based on current information but incorrect and non-updated PDR information is used in most descriptions at present in books and online. (Hopefully an official list will be added here soon). Effective dose range for SP is usually 60-90mg/day. Nardil is usually initiated at a low dose, and increased gradually over a period of several weeks to months. A common error is starting too high or increasing too quickly, and working with a Dr. experienced in prescribing MAOI's is important. MAOI related "hypertensive crisis" is rare in responsible patients, and the risk is certainly overemphasized in most medical literature. Many experts consider the MAOI's to be underutilized. Although it has been reported that the MAOI's have seen a small resurgance in recent years, it is likely they will continue to be used sparingly by MD's. This could change if/when the FDA approves the "selegiline patch" (see below on Eldepryl/selegiline).

Parnate (tranylcypromine): Parnate is not as effective as Nardil for SP, but occasionally may work well. Effects are variable, but people with Social Phobia most likely to benefit are those who also have significant depression and fatigue. Augmentation with a benzodiazepine (ie; Klonopin) can be useful in cases of excess agitation or stimulation.

Emsam / Eldepryl (selegiline): On February 28, 2006, the FDA approved selegiline (in a special patch form which carries the brand name (EMSAM) - for the treatment of major depression. The main advantage of the patch (transdermal) delivery over oral tablets are an elimination of the (albeit remote) risk of a "hyptensive crisis" which can rarely occur upon non-adherance to a few dietary restrictions. The elimination of dietary restrictions with Emsam hopefully will lead to an increase of Dr's taking a second look at the "old" MAOI's, which remain the most powerful antidepressants and whose risks are overstated by drug companies eager to sell their patented (profitable) SRI's. We have little experience with selegiline used as an antidepessant except that we know it works, and works well, as do the other MAOI's. Other uses for selegiline in psychiatry and neurology (especially) continue to be discovered as well. Prior to 2006, selegiline was used primarily for use in the treatment of Parkinson's Disease, where it is taken at low doses (oral 5-10mg per day) to boost the effects of L-DOPA, a powerful mainstay dopamine agonist treatment in Parkinson's Disease. (At very low doses selegiline selectively boosts dopamine in the brain). The approval of Emsam by the FDA is good news. It means that Dr's can feel safe in prescribing an MAOI to patients which is officially cleared by the FDA as not requiring any dietary retrictions.

Aurorix (moclobemide): During the mid 1990's 2 early studies in South America showed high rates of efficacy for moclobemide in the treatment of SP. Unfortunately, two larger North American studies in the late 1990's showed no efficacy at all. While study data is conflicting, real world evidence is that moclobemide is no more effective in the treatment of SP than are the SSRI's. Moclobemide does have some advantages (and disavantages) relative to the SSRI's. Moclobomide is equally effective as an antidepressant and causes no sexual side effects or sedation. However, moclobemide is less effective than the SSRI's in the treatment of most anxiety disorders.


--------------------------------------------------------------------------------
Benzodiazepines

Long term use of benzodiazepines remains controversial. About 10 are available but Klonopin is by far the most effective for SP. Xanax is sometimes helpful also.

Klonopin (clonazepam): Klonopin is extremely effective for SP and usually works great. Klonopin can be taken either "as needed" or everday. "As needed" (prn) use can be done up to twice per week, and will usually provide excellent effect within 30 minutes, lasting several hours to 1 day (typical dose .25-.75mg). Taken "long term", Klonopin may be used alone, although sometimes a non-sedating antidepressant is added if depression also exists. Effective dose in long term use usually ranges from 1-5 mg/day (dose should be raised slowly over a period of weeks to months). If energy is sub-par but there is no "depression", the addition of low dose stimulant (caffeine, Provigil) may be helpful. Klonopin works so well that taking too much can result in "disinhibition", similar to the opposite of SP. Other phobias, excessive worrying and fear are likely to diminish also.

Xanax XR (alprazolam): Occasionally may be helpful, especially for women. Alprazolam has a short half life which may limit its utility in long term use. This problem may have been lessened with an "XR" version released in the USA in 2003. Males in particular may find Xanax XR to be too sedating.

Myths About Benzodiazepines:
* "Benzodiazepines are addictive": FALSE for non drug addicts with anxiety disorders.
* "Benzodiazepines are hard to quit": FALSE (for SP, not GAD). Taper slow. Can cross-taper gabapentin if desired.
* "Benzodiazepine dose keeps escalating": FALSE. Dose stabilizes after a few months with continued efficacy.

Possible Drawbacks of Long Term Benzodiazepine Use:
* Depression may be aggrevated.
* Reduced mental sharpness may occur.
* Reduced motivation may occur.


--------------------------------------------------------------------------------
Non-Benzodiazepine 'Anxiolytics' (anti-anxiety agents)

This is a "catch all" section for medications which have anti-anxiety properties but which are not classified as antidepressants, benzodiazepines, anticonvulsants, etc.

Buspar (buspirone): Buspar was approved by the FDA specifically for the treatment of Generalized Anxiety Disorder. Unfortunately Buspar is completely ineffective in the treatment of primary Social Anxiety Disorder. Even an official "Social Phobia Committee" of doctors stated that Buspar (which IS still on patent) "has no place in the treatment of Social Anxiety Disorder". Real world experience confirms that Buspar is of no use in the treatment of primary generalized SP. It may be helpful for those who have *primary* GAD, however, it is not even used much for that purpose.

Inderal (propranolol): Propranolol is a medication used to help lower blood pressure. Propranolol may be helpful in *discrete* Social Phobias (a milder type of SP where only a small number of social situations cause difficulty - ie; public speaking). Propranolol blocks the "fight or flight" response - but little else - and has been shown to be of no benefit in *generalized* primary Social Phobia.

Propranolol has long been used by musicians and other performers who have "butterflies" or other mild physical symptoms of "stage fright". Propranolol is also used frequently off-label to treat essential tremor.

Neurontin (gabapentin): See "Anticonvulsants"


--------------------------------------------------------------------------------
Anticonvulsants

A number of new anticonvulsants have been, or will be, released between 2000-2010, and several of them have been considered as possible treatments for Social Anxiety Disorder. None of the newer anticonvulsants (some of which do have some general anti-anxiety qualities) appear to be of much use in the treatment of primary generalized SP. Neurontin (gabapentin) and Lyrica (pregabalin) fall into this category, and Keppra appears likely to as well. Many newer anticonvulsants like gabapentin and pregabalin are not even especially effective anti-seizure medications, and manufacturers are aggressively seeking alternative, FDA approved (patented) uses for them.

Valproate (valproic acid):

Neurontin (gabapentin): Occasionally slightly effective for SP. Common side effects: sedation, apathy, impaired cognition, imbalance. The manufacturer has recently been under legal attack on charges relating to "lack of efficacy" and "aggressive illicit marketing".

Lyrica (pregabalin): Very similar to gabapentin, but with a longer halflife. As with gabapentin, occasionally slightly effective. Common side effects: sedation, apathy, impaired cognition, imbalance.

Keppra (levetiracetam):

Lamictal (lamotrigine):


--------------------------------------------------------------------------------
Resources

Research and Medication:
Search Pubmed

Books:
Social Phobia: From Shyness to Stagefright John Marshall, 1995
Essential Guide to Psychiatric Drugs Jack Gorman, 1997, 3rd rev.
Feeling Good David Burns, 1999

Site Author: Chad Miller, 2000-2008

 

Re: Social phobia was diagnosed in 50% of PD patients.

Posted by Phillipa on August 14, 2008, at 12:46:10

In reply to Re: Social phobia was diagnosed in 50% of PD patients. » Marty, posted by Phillipa on August 14, 2008, at 12:38:42

More related to Parkinsons. Phillipa

PARKINSON'S DISEASE: DEPRESSION, PERSONALITY AND ANXIETY

To the passive observer, people with Parkinson's disease may appear to be depressed (and possibly to the same observer, people who are depressed could look parkinsonian). Appearances can be deceptive and there have been a number of studies into depression in Parkinson's.

Diagnosing depression in Parkinson's can be difficult because many of the symptoms of Parkinson's are also symptoms of depression. Many people with Parkinson's have weight loss, sleep disturbance, fatigue and slowing down and these are also things doctors are looking for in diagnosing depression.

It has been suggested to doctors that they ignore these signs in someone with Parkinson's and look for other symptoms such as decreased concentration and feelings of worthlessness as symptoms of depression. It has also been suggested that doctors who see signs such as sleep disturbance and fatigue should take into account that this could be depression, particularly as these symptoms will sometimes respond to antidepressants.

Sleep disturbances are a major symptom of depression and studies have shown that Parkinson's patients with major depression had more sleep disturbance and also more pain than people who were not depressed.

Other studies have shown that while anxiety and depression occur together with sleep problems, they do not contribute to changes in quality of sleep. This would seem to indicate that it is the disease itself that is that major cause of disturbed sleep, rather than depression or anxiety.

It is clear that many people with Parkinson's do suffer from depression, even though the mechanism may be in doubt. Studies have shown that people with Parkinson's have higher levels of depression than people with similar levels of disability from another cause, and that levels of depression are not related to the severity of Parkinson's symptoms. This seems to support the idea that the depression can be a part of the disease itself.

The fact that about 20 per cent of people diagnosed with Parkinson's suffer from depression prior to being diagnosed would also seem to indicate that the depression is part of the disease process rather than a result of diagnosis or living with Parkinson's. Other studies show higher levels of depression just after diagnosis and in the late stages of the condition, indicating that some people may suffer from depression as a reaction to having Parkinson's and some of the difficulties it creates.

The number of people with Parkinson's who are depressed is generally accepted at being about 40 per cent. One recent study of 105 consecutive patients with Parkinson's showed 21 per cent with major depression and 20 per cent with minor depression. Another study of 247 consecutive patients showed 25.5 per cent with major depression, and 17 per cent minor.

Most of these studies are of clinic patients and community-based studies tend to show lower levels. One study of 245 patients living in the community showed 7.7 per cent with major depression and 45.5 per cent with mild symptoms.

Who gets depressed, when and why is another topic for debate, and researchers do not seem to come up with clear answers. There does not seem to be a relationship between current age, the duration of Parkinson's and mood changes and there is no clear picture relating depression to age of onset. One study found that in people with early onset Parkinson's, depression was related to cognitive (thinking) problems and depression in later onset linked with difficulties in activities of daily living (ADL). Another study found that depression in younger onset patients was related to difficulties in ADL only.

A number of studies have shown that depression can affect the cognitive functions in Parkinson's. The area of the brain associated with motivation, prediction and reward has more dopamine cells damaged in people who suffer from major depression than would be expected. It also seems that the cognitive difficulties associated with Parkinson's are of a particular type and that the degree of depression influences the amount rather than the character of this cognitive impairment.

Major depression in Parkinson's is also associated with a decline in normal functioning in daily tasks, so treating depression can help people improve their ability to cope with daily life.

The type of depression suffered by those with Parkinson's seems to be different from a 'normal' depression: greater anxiety, more sadness, pessimism, irritability and ideas of suicide, less guilt, self punishment, feeling of failure, hallucinations and delusions and actual suicide.

A number of drugs are used to treat depression in Parkinson's but there have been very few studies which have examined their effectiveness. Different antidepressants have been used successfully, although up to 30 per cent of patients with depression could be resistant to antidepressants. An analysis of the medications used to treat more than 2,000 people with Parkinson's indicated that the selective serotonin reuptake inhibitors (SSRIs) were used 51 per cent of the time, tricyclic antidepressants 41 per cent of the time and other medications 8 per cent. Drugs for depression are also used in combination with various Parkinson's medications. Some Parkinson's medications also have some antidepressant effects.

The 'Parkinson's personality'
Over the years, some researchers have developed the theory that there is a distinctive Parkinson's personality; a person who is 'introverted, industrious, rigidly moral, serious, stoic, non-impulsive, over-controlled, less talkative and flexible, cautious and depressed'. The existence of this personality type is still, however, speculative.

The concept of this distinctive Parkinson's personality has less credibility when people who have been diagnosed with Alzheimer's and Parkinson's have been shown to have similar personality traits, suggesting that these traits could be in part an adaptation to a chronic neurological condition.

Other researchers have found that people with Parkinson's have less 'novelty seeking' behaviour (described as rigid, stoic, slow tempered, frugal, orderly and persistent). This type of behaviour seems to be linked to dopamine related mechanisms, which would seem to indicate that if there are these personality traits, they may be related to the disease process itself.

Other studies have been unable to find a link between novelty seeking and depression in Parkinson's, but there does seem to be a link between depression and harm avoidance, which is a behaviour linked to other chemical mechanisms in Parkinson's.

There are several ways to interpret these studies linking personality and Parkinson's and at this stage it is hard to prove or disprove any of them. Here are some of the theories.

A particular personality type causes or contributes to the onset of Parkinson's.
Parkinson's causes a personality type.
Particular personality types and Parkinson's occur in common at-risk populations.
The personality seen in Parkinson's is a manifestation of depression.
Anxiety and Parkinson's
Anxiety is common in Parkinson's, affecting up to 40 per cent of people, and is often related to self consciousness about the symptoms, particularly tremor. It can take the form of a generalised anxiety, a panic disorder or a social phobia. Generally anxiety symptoms occur after the diagnosis of Parkinson's, but in some people it can be the first symptom.

Anxiety is often associated with depression. One study showed that of those patients with anxiety, 92 per cent also had depression and in another study of people with Parkinson's and depression, 67 per cent also had a diagnosed anxiety disorder. The drugs most commonly used to treat anxiety in Parkinson's are the benzodiazepines.

Some people with Parkinson's experience a condition called akathisia, a term used to describe an inner restlessness and an inability to keep still. This is found frequently in Parkinson's and should not be confused with anxiety.

Reference: 'Psychiatric Manifestations of Parkinson's Disease'. Vladimir S. Kostic, Institute of Neurology, CCS, Belgrade, Yugoslavia. Seminar presentation at the 5th International Congress of Parkinson's Disease and Movement Disorders, New

 

Re: Social phobia was diagnosed in 50% of PD patients. » Phillipa

Posted by Marty on August 14, 2008, at 15:29:10

In reply to Re: Social phobia was diagnosed in 50% of PD patients. » Marty, posted by Phillipa on August 14, 2008, at 12:38:42


Hi,

www.socialfear.com is a great site for people new to social phobia. What a primer on the subject! I wish I knew that site back in the 90's.. impossible since it started in 2000.
The creator of this site, Chad Miller, was a poster here a couple years ago I think.. can't remember where I saw that but I'm pretty sure.

/\/\arty

> Marty first up on google looks like a good view of all that is good for social phobia. Will try and find more with parkinsons. Love Phillipa
>
>
> Symptoms of Social Anxiety Disorder:
> Social Anxiety Disorder is a persistent fear of one or more situations in which the person is exposed to possible scrutiny by others and fears that he or she may do something or act in a way that will be humiliating or embarrassing. It exceeds normal "shyness" when it leads to excessive social avoidance and substantial social or occupational impairment. Feared activities may include most any type of social interaction, especially small groups, dating, parties, talking to strangers, restaurants, etc. Physical symptoms include "mind going blank", fast heartbeat, blushing, stomach ache. Cognitive distortions are a hallmark, and learned about in CBT. Thoughts are often self-defeating and inaccurate.
>
>
> Neurobiology of Social Anxiety Disorder:
> Dysregulation of neurotransmitter function in the brain is thought to play a key role in Social Phobia (SP). Specifically, dopamine (DA), serotonin (SE), and / or GABA dysfunction are hypothosized in most cases of SP. in varying degrees depending on the individual. The MAOI antidepressant "phenelzine" (Nardil) uniquely boosts levels of all three - and is probably the single most effective (single drug) treatment for Social Phobia.
>
> There is strong evidence for dopamine dysfunction in SP. Comorbidies with other DA hypofunction disorders such as atypical depression, dysthymia, attention deficit disorder (ADD), and alcoholism are common. It has been noted that those with generalized Liebowitz observed in comparison studies between the TCA "imipramine" (Tofranil) and the MAOI "phenelzine" (Nardil) that while phenelzine was extremely effective in treating Social Anxiety, imipramine showed no efficacy - with the primary difference in the two drugs being the marked pro-DA effect of Nardil.
>
> Since the 1990's, evidence has emerged that an area of the brain called the striatum is different in patients with generalized Social Anxiety Disorder. More recent studies have switched focus to the amygdala, where evidence of abnormality accumulates. The amygdala is a core "primitive" part of the brain where many "automatic" animal type functions are regulated or controlled, such as fear and startle response, anxiety, sex, and aggression.
>
>
> Research Past and Present:
> Current research trends lean towards earlier recognition and treatment of SP. As the "world's most neglected anxiety disorder" becomes more understood by the public, Social Anxiety Disorder will begin to be diagnosed far more frequently in the pre-teen or teen years, resulting in earlier treatment, more "normal" social development, and less later life complications. In my case, during my 3rd grade year I had a 2 months bout of "school phobia", which commonly predicts SP in adulthood. Although Nardil and Klonopin existed at that time, the psychiatric diagnosis of Social Phobia did not. It was not until the early 1990's that key studies began for the medication treatment of SP. Liebowitz (Nardil), and Davidson (Klonopin) were the early pioneers towards highly effective SP medication treatment. Nardil and Klonopin remain the most reliably effective medications to treat Social Anxiety Disorder.
>
>
> --------------------------------------------------------------------------------
> Treatments for Social Anxiety Disorder:
>
> Psychological Treatment:
> Among possible psychological treatments for Social Anxiety Disorder, the best studied are CBT (Cognitive Behavioral Therapy) and CGBT (Cognitive Group Behavioral Therapy). While CBT and CGBT can often be helpful, medication treatments have been shown to produce more robust and dramatic improvement of symptoms. Patients with mild symptoms (as well as children or adolescents with Social Anxiety), may wish to pursue CBT or CGBT treatment methods as their first approach, while those with more significant or stubborn symptoms may prefer to use CBT as an adjunct to medication treatment. Good CBT therapists for SP are located primarily in larger cities. The best places to look are probably at large University Clinics or Health Centers.
>
> Research suggests that "general" or "supportive" psychotherapy is also helpful for many patients with Social Anxiety Disorder. This is probably especially true in more moderate and severe cases where issues such as low self esteem and other psychological and/or adjustment difficulties may be more pervasive. Currently there is no evidence that CBT is more, or less, effective than other psychotherapy techniques in the treatment of Social Anxiety. There are no clear guidelines, and one is probably best off trusting their own instincts of what is best for them.
>
> Medication Treatment:
> Medication treatment is the "tried and true" method to effectively treat Social Anxiety Disorder. Research trials for the treatment of Social Anxiety are still limited primarily to "monotherapy" treatment (one drug by itself). In actual practice, it is often the case that 2 or more medications are used in combination (polypharmacy). There are likely to be many different treatments (single drug or combinations) which are helpful for a given individual. Experimentation affords one an opportunity to find out which treatments are most satisfactory for them. Despite increasing recognition of "the world's most neglected anxiety disorder" - most Dr's even now in *2007* continue to have relatively little experience (and even less skill) in treating patients with Social Anxiety. Patient self-education continues to play a key role for those wishing to ensure that they receive the appropriate medical intervention they deserve.
>
> A Medication Treatment Algorithm for Social Anxiety:
> One reasonable algorithm of trial is as follows:
> (Goal is typically effectiveness and tolerability over the long term):
>
> 1) Antidepressant
> a) SSRI, Effexor, moclobomide ... else try ...
> b) MAOI (Nardil)
>
> 2) Benzodiazepine
> a) Klonopin (alone)
> b) Klonopin + Antidepressant (any above)
> c) Xanax
>
> 3) May wish to augment (add) any of following: (Note: Most of these unstudied for SP)
> a) Provigil (modafinil): Mild stimulant. Very low doses 20-100mg/day, divided
> b) caffeine: Mild stimulant.
> c) Neurontin (gabapentin): Anticonvulsant, may be sedating
> d) Keppra (levetiracetam): Anticonvulsant, may be sedating
>
> CERTAIN COMBINATIONS OR SINGLE DRUGS DANGEROUS: CHECK WITH DOCTOR FOR ALL TREATMENT RECOMMENDATION
>
> --------------------------------------------------------------------------------
> SSRI's
>
> Several SSRI's have in recent years gained FDA approval in the treatment of Social Anxiety Disorder. During this time the SRI's have also come to be labeled the first line treatment for Social Anxiety Disorder in the general medical community.
>
> Two SSRI's (Paxil and Zoloft) and one SNRI (Effexor XR) - are the only FDA approved drugs for SP at this time. Because of these recent FDA approvals and a relatively low risk of serious adverse events related to overdose and drug interactions, the SRI's are quite easy and legally safe for general physicians and psychiatrists to prescribe. Most Dr's will now initially prescribe an SRI when a previously untreated patient presents with symptoms of Social Anxiety Disorder.
>
> SRI's are quite helpful in the treatment of SP symptoms. Their usefulness in SP is increased by the fact that they are effective not only in some of the direct symptoms of SP itself, but are also very helpful for a number of other common co-occurring disorders which may be present. These include dysthymia, depression, panic, general anxiety, and obsessive compulsive disorder (OCD).
>
> With the exception of Prozac, SSRI's are used predominantly by women in long term treatment, who tolerate and respond to them better than males.
>
> ------------------
>
> Prozac (fluoxetine): The "activating" SSRI with the least side effects - particularly for males. Considered an "atypical SSRI", with effects somewhere in between the SNRI "Effexor" and the other SSRI's.
>
> Zoloft (sertraline): May be activating or sedating. Common side effects: sexual dysfunction, apathy.
>
> Paxil CR (paroxetine): May be sedating. Common side effects: sexual dysfunction , apathy, weight gain.
>
> "Paxil CR" was released in early 2004 when the patent on "Paxil" expired, to acquire a new patent and retain inflated prices on the newer CR version. There is no known difference in efficacy between generic and "CR". There is limited need for a "CR" version since the half life of generic Paxil is near ideal; with an FDA recommended once daily dosing.
>
> Celexa (citalopram): May be activating or sedating. Common side effects: sexual dysfunction, apathy.
>
> Lexapro (escitalopram): May be activating or sedating. Common side effects: sexual dysfunction, apathy.
>
> Lexapro was released in 2002 when the patent expired on Celexa (same manufacturer) to acquire a new patent and retain inflated prices on the newer version. Lexapro contains the same active ingredient as Celexa (escitalopram) with no known clinical differences between the two medications.
>
>
> --------------------------------------------------------------------------------
> "New generation" Antidepressants
>
> These include Effexor XR, Cymbalta, Wellbutrin SR, Remeron and Serzone. They each have fairly different characteristics from each other and from the SSRI's. Used alone, any of them may be mildly helpful for primary SP. Augmentation may modify the effects of any of these to create a more effective SP treatment.
>
> Effexor XR (venlafaxine): Effexor is an "SNRI" (serotonin and norepinephrine reuptake inhibitor). The NE reuptake results in a more activating and energizing profile than that of the SSRI's. Effexor is usually only mildly helpful for primary SP when taken alone. It is a powerful antidepressant which is ironically also effective for GAD (Effexor often increases anxiety in patients with primary Social Anxiety Disorder).
>
> Cymbalta (duloxetine): Cybalta, like Effexor, is an "SNRI" (serotonin and norepinephrine reuptake inhibitor). Cymbalta, released in 2005, differs from Effexor mainly in that it is comparatively more noradrenergic. Cymbalta is not likely to be any more useful for primary Social Anxiety Disorder than Effexor XR ... if anything less so.
>
> Wellbutrin XR (bupropion): Wellbutrin boosts DA and NE, with little effect on SE. It is activating and does not cause weight gain or sexual side effects. It is more similar to stimulants (especially Ritalin) - then to SRI's. It is effective in depression and dysthymia, and one study shows possible efficacy in SP. In practice it tends to leave most with SP still feeling quite anxious. The addition of a serotonergic axiolytic (especially Xanax) can be effective.
>
> Remeron (mirtazapine): Remeron enhances NE activity and has mixed SE effects (enhances 5ht(1) transmission but antagonizes 5ht(2) and 5ht(3) receptors). Remeron also has strong antihistamine effects, which may explain it's prominent sedative effects. Overall, Remeron usually causes significant sedation and/or irritability, and is infrequently used.
>
>
> --------------------------------------------------------------------------------
> TCA's
>
> The TCA's (tricyclic) antidepressants are ineffective in the treatment of primary SP. TCA's emerged in the 1950's along with the MAOI's, and while there are still about 10 of them marketed in the USA, their use has been substantially replaced by the newer antidepressants.
>
> Tofranil (imipramine): This once popular TCA was often used for depression, panic, and GAD.
>
>
> --------------------------------------------------------------------------------
> MAOI's
>
> The MAOI "Nardil" is definitely the MOST powerful and effective antidepressant for Social Phobia.
>
> Nardil (phenelzine): Nardil usually works great for SP! It the "Gold Standard" antidepressant for SP. Nardil is excellent for many other anxiety and depressive disorders also. Reports of Nardil side effects are frequently exaggerated, particularly since Nardil's side effects typically take 2-4 months to diminish or disappear. After several months Nardil tends to cause less side effects than SRI's across comparable dose ranges, with the exception of Prozac. Dietary retrictions are quite minimal based on current information but incorrect and non-updated PDR information is used in most descriptions at present in books and online. (Hopefully an official list will be added here soon). Effective dose range for SP is usually 60-90mg/day. Nardil is usually initiated at a low dose, and increased gradually over a period of several weeks to months. A common error is starting too high or increasing too quickly, and working with a Dr. experienced in prescribing MAOI's is important. MAOI related "hypertensive crisis" is rare in responsible patients, and the risk is certainly overemphasized in most medical literature. Many experts consider the MAOI's to be underutilized. Although it has been reported that the MAOI's have seen a small resurgance in recent years, it is likely they will continue to be used sparingly by MD's. This could change if/when the FDA approves the "selegiline patch" (see below on Eldepryl/selegiline).
>
> Parnate (tranylcypromine): Parnate is not as effective as Nardil for SP, but occasionally may work well. Effects are variable, but people with Social Phobia most likely to benefit are those who also have significant depression and fatigue. Augmentation with a benzodiazepine (ie; Klonopin) can be useful in cases of excess agitation or stimulation.
>
> Emsam / Eldepryl (selegiline): On February 28, 2006, the FDA approved selegiline (in a special patch form which carries the brand name (EMSAM) - for the treatment of major depression. The main advantage of the patch (transdermal) delivery over oral tablets are an elimination of the (albeit remote) risk of a "hyptensive crisis" which can rarely occur upon non-adherance to a few dietary restrictions. The elimination of dietary restrictions with Emsam hopefully will lead to an increase of Dr's taking a second look at the "old" MAOI's, which remain the most powerful antidepressants and whose risks are overstated by drug companies eager to sell their patented (profitable) SRI's. We have little experience with selegiline used as an antidepessant except that we know it works, and works well, as do the other MAOI's. Other uses for selegiline in psychiatry and neurology (especially) continue to be discovered as well. Prior to 2006, selegiline was used primarily for use in the treatment of Parkinson's Disease, where it is taken at low doses (oral 5-10mg per day) to boost the effects of L-DOPA, a powerful mainstay dopamine agonist treatment in Parkinson's Disease. (At very low doses selegiline selectively boosts dopamine in the brain). The approval of Emsam by the FDA is good news. It means that Dr's can feel safe in prescribing an MAOI to patients which is officially cleared by the FDA as not requiring any dietary retrictions.
>
> Aurorix (moclobemide): During the mid 1990's 2 early studies in South America showed high rates of efficacy for moclobemide in the treatment of SP. Unfortunately, two larger North American studies in the late 1990's showed no efficacy at all. While study data is conflicting, real world evidence is that moclobemide is no more effective in the treatment of SP than are the SSRI's. Moclobemide does have some advantages (and disavantages) relative to the SSRI's. Moclobomide is equally effective as an antidepressant and causes no sexual side effects or sedation. However, moclobemide is less effective than the SSRI's in the treatment of most anxiety disorders.
>
>
> --------------------------------------------------------------------------------
> Benzodiazepines
>
> Long term use of benzodiazepines remains controversial. About 10 are available but Klonopin is by far the most effective for SP. Xanax is sometimes helpful also.
>
> Klonopin (clonazepam): Klonopin is extremely effective for SP and usually works great. Klonopin can be taken either "as needed" or everday. "As needed" (prn) use can be done up to twice per week, and will usually provide excellent effect within 30 minutes, lasting several hours to 1 day (typical dose .25-.75mg). Taken "long term", Klonopin may be used alone, although sometimes a non-sedating antidepressant is added if depression also exists. Effective dose in long term use usually ranges from 1-5 mg/day (dose should be raised slowly over a period of weeks to months). If energy is sub-par but there is no "depression", the addition of low dose stimulant (caffeine, Provigil) may be helpful. Klonopin works so well that taking too much can result in "disinhibition", similar to the opposite of SP. Other phobias, excessive worrying and fear are likely to diminish also.
>
> Xanax XR (alprazolam): Occasionally may be helpful, especially for women. Alprazolam has a short half life which may limit its utility in long term use. This problem may have been lessened with an "XR" version released in the USA in 2003. Males in particular may find Xanax XR to be too sedating.
>
> Myths About Benzodiazepines:
> * "Benzodiazepines are addictive": FALSE for non drug addicts with anxiety disorders.
> * "Benzodiazepines are hard to quit": FALSE (for SP, not GAD). Taper slow. Can cross-taper gabapentin if desired.
> * "Benzodiazepine dose keeps escalating": FALSE. Dose stabilizes after a few months with continued efficacy.
>
> Possible Drawbacks of Long Term Benzodiazepine Use:
> * Depression may be aggrevated.
> * Reduced mental sharpness may occur.
> * Reduced motivation may occur.
>
>
> --------------------------------------------------------------------------------
> Non-Benzodiazepine 'Anxiolytics' (anti-anxiety agents)
>
> This is a "catch all" section for medications which have anti-anxiety properties but which are not classified as antidepressants, benzodiazepines, anticonvulsants, etc.
>
> Buspar (buspirone): Buspar was approved by the FDA specifically for the treatment of Generalized Anxiety Disorder. Unfortunately Buspar is completely ineffective in the treatment of primary Social Anxiety Disorder. Even an official "Social Phobia Committee" of doctors stated that Buspar (which IS still on patent) "has no place in the treatment of Social Anxiety Disorder". Real world experience confirms that Buspar is of no use in the treatment of primary generalized SP. It may be helpful for those who have *primary* GAD, however, it is not even used much for that purpose.
>
> Inderal (propranolol): Propranolol is a medication used to help lower blood pressure. Propranolol may be helpful in *discrete* Social Phobias (a milder type of SP where only a small number of social situations cause difficulty - ie; public speaking). Propranolol blocks the "fight or flight" response - but little else - and has been shown to be of no benefit in *generalized* primary Social Phobia.
>
> Propranolol has long been used by musicians and other performers who have "butterflies" or other mild physical symptoms of "stage fright". Propranolol is also used frequently off-label to treat essential tremor.
>
> Neurontin (gabapentin): See "Anticonvulsants"
>
>
> --------------------------------------------------------------------------------
> Anticonvulsants
>
> A number of new anticonvulsants have been, or will be, released between 2000-2010, and several of them have been considered as possible treatments for Social Anxiety Disorder. None of the newer anticonvulsants (some of which do have some general anti-anxiety qualities) appear to be of much use in the treatment of primary generalized SP. Neurontin (gabapentin) and Lyrica (pregabalin) fall into this category, and Keppra appears likely to as well. Many newer anticonvulsants like gabapentin and pregabalin are not even especially effective anti-seizure medications, and manufacturers are aggressively seeking alternative, FDA approved (patented) uses for them.
>
> Valproate (valproic acid):
>
> Neurontin (gabapentin): Occasionally slightly effective for SP. Common side effects: sedation, apathy, impaired cognition, imbalance. The manufacturer has recently been under legal attack on charges relating to "lack of efficacy" and "aggressive illicit marketing".
>
> Lyrica (pregabalin): Very similar to gabapentin, but with a longer halflife. As with gabapentin, occasionally slightly effective. Common side effects: sedation, apathy, impaired cognition, imbalance.
>
> Keppra (levetiracetam):
>
> Lamictal (lamotrigine):
>
>
> --------------------------------------------------------------------------------
> Resources
>
> Research and Medication:
> Search Pubmed
>
> Books:
> Social Phobia: From Shyness to Stagefright John Marshall, 1995
> Essential Guide to Psychiatric Drugs Jack Gorman, 1997, 3rd rev.
> Feeling Good David Burns, 1999
>
>
>
> Site Author: Chad Miller, 2000-2008
>

 

Re: Social phobia was diagnosed in 50% of PD patients. » Phillipa

Posted by Marty on August 14, 2008, at 15:33:01

In reply to Re: Social phobia was diagnosed in 50% of PD patients., posted by Phillipa on August 14, 2008, at 12:46:10

Again very interesting.

Thanks,
/\/\arty

---
> More related to Parkinsons. Phillipa
>
> PARKINSON'S DISEASE: DEPRESSION, PERSONALITY AND ANXIETY
>
>
>
> To the passive observer, people with Parkinson's disease may appear to be depressed (and possibly to the same observer, people who are depressed could look parkinsonian). Appearances can be deceptive and there have been a number of studies into depression in Parkinson's.
>
> Diagnosing depression in Parkinson's can be difficult because many of the symptoms of Parkinson's are also symptoms of depression. Many people with Parkinson's have weight loss, sleep disturbance, fatigue and slowing down and these are also things doctors are looking for in diagnosing depression.
>
> It has been suggested to doctors that they ignore these signs in someone with Parkinson's and look for other symptoms such as decreased concentration and feelings of worthlessness as symptoms of depression. It has also been suggested that doctors who see signs such as sleep disturbance and fatigue should take into account that this could be depression, particularly as these symptoms will sometimes respond to antidepressants.
>
> Sleep disturbances are a major symptom of depression and studies have shown that Parkinson's patients with major depression had more sleep disturbance and also more pain than people who were not depressed.
>
> Other studies have shown that while anxiety and depression occur together with sleep problems, they do not contribute to changes in quality of sleep. This would seem to indicate that it is the disease itself that is that major cause of disturbed sleep, rather than depression or anxiety.
>
> It is clear that many people with Parkinson's do suffer from depression, even though the mechanism may be in doubt. Studies have shown that people with Parkinson's have higher levels of depression than people with similar levels of disability from another cause, and that levels of depression are not related to the severity of Parkinson's symptoms. This seems to support the idea that the depression can be a part of the disease itself.
>
> The fact that about 20 per cent of people diagnosed with Parkinson's suffer from depression prior to being diagnosed would also seem to indicate that the depression is part of the disease process rather than a result of diagnosis or living with Parkinson's. Other studies show higher levels of depression just after diagnosis and in the late stages of the condition, indicating that some people may suffer from depression as a reaction to having Parkinson's and some of the difficulties it creates.
>
> The number of people with Parkinson's who are depressed is generally accepted at being about 40 per cent. One recent study of 105 consecutive patients with Parkinson's showed 21 per cent with major depression and 20 per cent with minor depression. Another study of 247 consecutive patients showed 25.5 per cent with major depression, and 17 per cent minor.
>
> Most of these studies are of clinic patients and community-based studies tend to show lower levels. One study of 245 patients living in the community showed 7.7 per cent with major depression and 45.5 per cent with mild symptoms.
>
> Who gets depressed, when and why is another topic for debate, and researchers do not seem to come up with clear answers. There does not seem to be a relationship between current age, the duration of Parkinson's and mood changes and there is no clear picture relating depression to age of onset. One study found that in people with early onset Parkinson's, depression was related to cognitive (thinking) problems and depression in later onset linked with difficulties in activities of daily living (ADL). Another study found that depression in younger onset patients was related to difficulties in ADL only.
>
> A number of studies have shown that depression can affect the cognitive functions in Parkinson's. The area of the brain associated with motivation, prediction and reward has more dopamine cells damaged in people who suffer from major depression than would be expected. It also seems that the cognitive difficulties associated with Parkinson's are of a particular type and that the degree of depression influences the amount rather than the character of this cognitive impairment.
>
> Major depression in Parkinson's is also associated with a decline in normal functioning in daily tasks, so treating depression can help people improve their ability to cope with daily life.
>
> The type of depression suffered by those with Parkinson's seems to be different from a 'normal' depression: greater anxiety, more sadness, pessimism, irritability and ideas of suicide, less guilt, self punishment, feeling of failure, hallucinations and delusions and actual suicide.
>
> A number of drugs are used to treat depression in Parkinson's but there have been very few studies which have examined their effectiveness. Different antidepressants have been used successfully, although up to 30 per cent of patients with depression could be resistant to antidepressants. An analysis of the medications used to treat more than 2,000 people with Parkinson's indicated that the selective serotonin reuptake inhibitors (SSRIs) were used 51 per cent of the time, tricyclic antidepressants 41 per cent of the time and other medications 8 per cent. Drugs for depression are also used in combination with various Parkinson's medications. Some Parkinson's medications also have some antidepressant effects.
>
> The 'Parkinson's personality'
> Over the years, some researchers have developed the theory that there is a distinctive Parkinson's personality; a person who is 'introverted, industrious, rigidly moral, serious, stoic, non-impulsive, over-controlled, less talkative and flexible, cautious and depressed'. The existence of this personality type is still, however, speculative.
>
> The concept of this distinctive Parkinson's personality has less credibility when people who have been diagnosed with Alzheimer's and Parkinson's have been shown to have similar personality traits, suggesting that these traits could be in part an adaptation to a chronic neurological condition.
>
> Other researchers have found that people with Parkinson's have less 'novelty seeking' behaviour (described as rigid, stoic, slow tempered, frugal, orderly and persistent). This type of behaviour seems to be linked to dopamine related mechanisms, which would seem to indicate that if there are these personality traits, they may be related to the disease process itself.
>
> Other studies have been unable to find a link between novelty seeking and depression in Parkinson's, but there does seem to be a link between depression and harm avoidance, which is a behaviour linked to other chemical mechanisms in Parkinson's.
>
> There are several ways to interpret these studies linking personality and Parkinson's and at this stage it is hard to prove or disprove any of them. Here are some of the theories.
>
> A particular personality type causes or contributes to the onset of Parkinson's.
> Parkinson's causes a personality type.
> Particular personality types and Parkinson's occur in common at-risk populations.
> The personality seen in Parkinson's is a manifestation of depression.
> Anxiety and Parkinson's
> Anxiety is common in Parkinson's, affecting up to 40 per cent of people, and is often related to self consciousness about the symptoms, particularly tremor. It can take the form of a generalised anxiety, a panic disorder or a social phobia. Generally anxiety symptoms occur after the diagnosis of Parkinson's, but in some people it can be the first symptom.
>
> Anxiety is often associated with depression. One study showed that of those patients with anxiety, 92 per cent also had depression and in another study of people with Parkinson's and depression, 67 per cent also had a diagnosed anxiety disorder. The drugs most commonly used to treat anxiety in Parkinson's are the benzodiazepines.
>
> Some people with Parkinson's experience a condition called akathisia, a term used to describe an inner restlessness and an inability to keep still. This is found frequently in Parkinson's and should not be confused with anxiety.
>
> Reference: 'Psychiatric Manifestations of Parkinson's Disease'. Vladimir S. Kostic, Institute of Neurology, CCS, Belgrade, Yugoslavia. Seminar presentation at the 5th International Congress of Parkinson's Disease and Movement Disorders, New
>

 

Re: Social phobia was diagnosed in 50% of PD patie

Posted by dcruik518 on August 14, 2008, at 15:35:18

In reply to Social phobia was diagnosed in 50% of PD patients., posted by Marty on August 14, 2008, at 11:55:53

Do you mean experience with dopamine agonists? Those are the drugs used to treat parkinsons. I've tried Requip, Bromocritptine, and levodopa and they have an anti-anxiety effect on me, but I've found they also interfere with a voice disorder I have, unless I combine it with anti-epileptic drugs. At first they worked well. It's weird how two totally different drugs like Requip and Seroquel can actually feel quite similar in their sedating/calming effects. Anyone know why that might be?

 

Re: Social phobia was diagnosed in 50% of PD patie » dcruik518

Posted by Marty on August 14, 2008, at 15:53:07

In reply to Re: Social phobia was diagnosed in 50% of PD patie, posted by dcruik518 on August 14, 2008, at 15:35:18


> It's weird how two totally different drugs like Requip and Seroquel can actually feel quite similar in their sedating/calming effects. Anyone know why that might be?
---
I guess both (up/down)regulate the dopamine receptors or/and transporter. Just a quick sketchy guess... my brain is pretty much turned-off today, sorry.

I think I'll try Mirapex .. It seems it's pretty good for Bipolar depression. What do you think of it ? I guess you did some research on it.

/\/\arty

 

Re: Social phobia was diagnosed in 50% of PD patie

Posted by desolationrower on August 14, 2008, at 18:35:33

In reply to Re: Social phobia was diagnosed in 50% of PD patie, posted by dcruik518 on August 14, 2008, at 15:35:18

> Do you mean experience with dopamine agonists? Those are the drugs used to treat parkinsons. I've tried Requip, Bromocritptine, and levodopa and they have an anti-anxiety effect on me, but I've found they also interfere with a voice disorder I have, unless I combine it with anti-epileptic drugs. At first they worked well. It's weird how two totally different drugs like Requip and Seroquel can actually feel quite similar in their sedating/calming effects. Anyone know why that might be?

a low dose of an atypical antispychotic will enhance cortical dopamine release, and not give significant d2 blockade.

 

Re: Social phobia was diagnosed in 50% of PD patie » desolationrower

Posted by Marty on August 14, 2008, at 20:02:01

In reply to Re: Social phobia was diagnosed in 50% of PD patie, posted by desolationrower on August 14, 2008, at 18:35:33

> a low dose of an atypical antispychotic will enhance cortical dopamine release, and not give significant d2 blockade.
---
Could you provide some example of what could be those low dose for some of the currently popular atypical antipsychotic ?

Thanks,
/\/\arty

 

Re: Social phobia was diagnosed in 50% of PD patients. » Marty

Posted by SLS on August 15, 2008, at 5:59:36

In reply to Social phobia was diagnosed in 50% of PD patients., posted by Marty on August 14, 2008, at 11:55:53

Hi Marty.

This site might contain some useful information.

http://www.parkinsons-information-exchange-network-online.com/


- Scott


This is the end of the thread.


Show another thread

URL of post in thread:


Psycho-Babble Medication | Extras | FAQ


[dr. bob] Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.